RETRACTED: Increased serum vascular endothelial growth factor level in Churg-Strauss syndrome (Retracted article. See vol. 134, pg. 893, 2008)

被引:16
作者
Mitsuyama, H [1 ]
Matsuyama, W [1 ]
Iwakawa, J [1 ]
Higashimoto, I [1 ]
Watanabe, M [1 ]
Osame, M [1 ]
Arimura, K [1 ]
机构
[1] Kagoshima Univ Hosp, Div Resp Med, Resp & Stress Care Ctr, Kagoshima 8908520, Japan
关键词
allergy; asthma; eosinophils; vasculitis;
D O I
10.1378/chest.129.2.407
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Churg-Strauss syndrome (CSS) is a rare form of systemic vasculitis occurring in patients with asthma and hypereosinophilia. For optimal treatment, prompt distinction of CSS from asthma is necessary; however, there are few serologic screening markers for this purpose. Vascular endothelial growth factor (VEGF), a vascular permeability factor, has been associated with other systemic vasculitis such as Wegener granulomatosis and giant-cell arteritis. Objective: The aim of this study was to clarify the clinical value of the measurement of serum VEGF for the distinction of CSS from asthma. Methods: We investigated serum VEGF levels in 18 CSS patients, 19 asthma patients, and 12 acute bronchitis patients. We also performed immunohistochemical analysis for VEGF. Results: The serum VEGF levels of CSS patients were significantly higher than those of asthma patients and acute bronchitis patients. The sensitivity and specificity to distinguish CSS from asthma were 93.3% and 81.8%, respectively (cutoff, 600 pg/mL). Infiltrating eosinophils stained intensely positive for VEGF, and serum VEGF levels showed a significant correlation with peripheral eosinophil counts. Serum VEGF levels decreased significantly after therapy (p < 0.001). The infiltrating eosinophils in the CSS lesion stained positive for VEGF in the immunohistochemical analysis. Conclusion: VEGF is one of the useful screening markers for the distinction of CSS from asthma. We suggest that VEGF might be associated with the pathogenesis of CSS.
引用
收藏
页码:407 / 411
页数:5
相关论文
共 26 条
  • [1] BREIER G, 1992, DEVELOPMENT, V114, P521
  • [2] Churg-Strauss syndrome
    Conron, M
    Beynon, HLC
    [J]. THORAX, 2000, 55 (10) : 870 - 877
  • [3] DVORAK HF, 1995, AM J PATHOL, V146, P1029
  • [4] Pulmonary eosinophilia associated with montelukast
    Franco, J
    Artés, MJ
    [J]. THORAX, 1999, 54 (06) : 558 - 560
  • [5] Churg-Strauss syndrome - Clinical study and long-term follow-up of 96 patients
    Guillevin, L
    Cohen, P
    Gayraud, M
    Lhote, F
    Jarrousse, B
    Casassus, P
    [J]. MEDICINE, 1999, 78 (01) : 26 - 37
  • [6] Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood
    Gunsilius, E
    Petzer, A
    Stockhammer, G
    Nussbaumer, W
    Schumacher, P
    Clausen, J
    Gastl, G
    [J]. ONCOLOGY, 2000, 58 (02) : 169 - 174
  • [7] Primary vasculitis in a Norwegian community hospital: A retrospective study
    Haugeberg, G
    Bie, R
    Bendvold, A
    Larsen, AS
    Johnsen, V
    [J]. CLINICAL RHEUMATOLOGY, 1998, 17 (05) : 364 - 368
  • [8] Hellmich B, 2003, CLIN EXP RHEUMATOL, V21, pS69
  • [9] Expression of vascular endothelial growth factor by human eosinophils: Upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5
    Horiuchi, T
    Weller, PF
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 17 (01) : 70 - 77
  • [10] Formation of new vasa vasorum in vasculitis -: Production of angiogenic cytokines by multinucleated giant cells
    Kaiser, M
    Younge, B
    Björnsson, J
    Goronzy, JJ
    Weyand, CM
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (03) : 765 - 774